Clinical Trials Logo
  1. Home
  2. Sickle Cell Disease
  3. NCT02179359
  4. Details
NCT02179359 Clinical Trial

Hematopoietic Stem Cell Transplant for High Risk Hemoglobinopathies

Sickle Cell Disease Clinical Trial

Official title:
MT2014-10C: Allogeneic Hematopoietic Stem Cell Transplant for Patients With High Risk Hemoglobinopathies and Other Red Cell Transfusion Dependent Disorders

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT02179359
Other study ID # 2014OC034
Secondary ID MT2014-10C
Status Recruiting
Phase N/A
First received
Last updated
Start date September 2, 2014
Est. completion date August 2025

Study information
Verified date February 2024
Source Masonic Cancer Center, University of Minnesota
Contact Lisa Burke
Phone 612-273-8482
Email lburke3@Fairview.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a study to collect the outcomes of stem cell transplantation for patients with hematologic diseases other than cancer.

Recruitment information / eligibility
Status Recruiting
Enrollment 25
Est. completion date August 2025
Est. primary completion date January 2025
Accepts healthy volunteers No
Gender All
Age group N/A to 55 Years
Eligibility Inclusion Criteria: - Diagnosis of Sickle Cell Disease, Thalassemia, Diamond Blackfan Anemia or other non-malignant hematologic disorders for which a stem cell transplant is indicated - Acceptable stem cell source identified - Performance status of = 70% (Karnofsky),or = 70 (Lansky play score) - Creatinine <2.0 mg/dl for adults or glomerular filtration rate > 50 ml/min for children - Bilirubin, Aspartate Aminotransferase, Alkaline phosphatase <5 times the upper limit of institutional normal - Absence of decompensated congestive heart failure, or uncontrolled arrhythmia and left ventricular ejection fraction > 40% Exclusion Criteria: - active, uncontrolled infection - pregnant or breastfeeding - HIV positive

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Reduced Toxicity Ablative Regimen
Anti-thymocyte Globulin (ATG) Fludarabine Busulfan Stem Cell Infusion Day 0
• Reduced Intensity Preparative Regimen
Alemtuzumab Cyclophosphamide Fludarabine Total Body Irradiation (TBI) Stem Cell Infusion Day 0
• Myeloablative Preparative Regimen
Alemtuzumab Cyclophosphamide Busulfan Stem Cell Infusion Day 0

Locations
Country Name City State
United States University of Minnesota Medical Center, Fairview Minneapolis Minnesota

Sponsors (1)
Lead Sponsor Collaborator
Masonic Cancer Center, University of Minnesota

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary incidence of graft failure 42 days
Secondary overall survival 6 months, 1 and 2 years
Secondary disease free survival patient no longer needing red blood cell transfusion and/or a hemoglobin S level at that of the donor ( sickle cell disease only) 6 months, 1 and 2 years
See also
  Status Clinical Trial Phase
Completed NCT02227472 - Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease
Recruiting NCT06301893 - Uganda Sickle Surveillance Study (US-3)
Recruiting NCT04398628 - ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Completed NCT02522104 - Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH) Phase 4
Recruiting NCT04688411 - An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease N/A
Terminated NCT03615924 - Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease Phase 3
Recruiting NCT03937817 - Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
Completed NCT04917783 - Health Literacy - Neurocognitive Screening in Pediatric SCD N/A
Completed NCT04134299 - To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease N/A
Completed NCT02580565 - Prevalence of Problematic Use of Equimolar Mixture of Oxygen and Nitrous Oxide and Analgesics in the Sickle-cell Disease
Recruiting NCT04754711 - Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition N/A
Completed NCT04388241 - Preliminary Feasibility and Efficacy of Behavioral Intervention to Reduce Pain-Related Disability in Pediatric SCD N/A
Recruiting NCT05431088 - A Phase 2/3 Study in Adult and Pediatric Participants With SCD Phase 2/Phase 3
Completed NCT01158794 - Genes Influencing Iron Overload State
Recruiting NCT03027258 - Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome N/A
Withdrawn NCT02960503 - Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease Phase 1/Phase 2
Completed NCT02567695 - A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects Phase 1
Completed NCT02567682 - Drug Interaction Study of GBT440 With Caffeine, S-warfarin, Omeprazole, and Midazolam in Healthy Subjects Phase 1
Withdrawn NCT02630394 - A Pilot Study of Azithromycin Prophylaxis for Acute Chest Syndrome in Sickle Cell Disease Phase 1
Completed NCT02620488 - A Brief Laboratory-Based Hypnosis Session for Pain in Sickle Cell Disease N/A